In addition the APOLLOB data further strengthen our confidence in our Phase 3 HELIOSB study of vutrisiran in ATTR amyloidosis with cardiomyopathy which is expected to report out in early 2024 said Yvonne Greenstreet MBChB Chief Executive Oicer of Alnylam